Correction to: Adverse Effects of Physostigmine

Ann M Arens^{1

2}, Tom Kearney^{3

4}

Affiliations

¹ Minnesota Poison Control System, Minneapolis, MN, USA. Ann.Arens@hcmed.org.
² Hennepin Healthcare, Department of Emergency Medicine, Hennepin County Medical Center, 701 Park Avenue, MC-R2, Minneapolis, MN, 55415, USA. Ann.Arens@hcmed.org.
³ California Poison Control System, San Francisco Division, San Francisco, CA, USA.
⁴ San Francisco School of Pharmacy, University of California, San Francisco, CA, USA.

Published Erratum

Ann M Arens et al. J Med Toxicol. 2019 Oct.

. 2019 Oct;15(4):310.

doi: 10.1007/s13181-019-00730-1.

Ann M Arens^{1

2}, Tom Kearney^{3

4}

¹ Minnesota Poison Control System, Minneapolis, MN, USA. Ann.Arens@hcmed.org.
² Hennepin Healthcare, Department of Emergency Medicine, Hennepin County Medical Center, 701 Park Avenue, MC-R2, Minneapolis, MN, 55415, USA. Ann.Arens@hcmed.org.
³ California Poison Control System, San Francisco Division, San Francisco, CA, USA.
⁴ San Francisco School of Pharmacy, University of California, San Francisco, CA, USA.

Abstract

In "Adverse Effects of Physostigmine" by Arens et al in the July 2019 issue of JMT, reference #27 contains an error.

Adverse Effects of Physostigmine.
Arens AM, Kearney T. Arens AM, et al. J Med Toxicol. 2019 Jul;15(3):184-191. doi: 10.1007/s13181-019-00697-z. Epub 2019 Feb 11. J Med Toxicol. 2019. PMID: 30747326 Free PMC article. Review.